Immunohistochemical analysis of prostate cancer (CRPC) specimens unveiled a noteworthy association between SLFN5 expression and disease progression, along with a substantial correlation with an elevated risk of metastasis. The gene discussed is SLFN5; the disease is prostate carcinoma.